Molecular Profiles Demonstrates Technique for Measuring Surface Physical Properties of Pharmaceutical Materials for Inhalation
Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide, announces a new poster to demonstrate the ability of nanoPASS (nanoscale Predictive Analytical Screening Solution) to characterise the surface energy of an API material.
(Nottingham UK, 26 June, 2008) - Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide, announces a new poster to demonstrate the ability of nanoPASS (nanoscale Predictive Analytical Screening Solution) to characterise the surface energy of an API material. nanoPASS, an innovative new service platform, was launched earlier this year as a new addition to Molecular Profiles' nanoscale analytical services offering. This poster entitled "Measuring Surface Physical Properties of Pharmaceutical Materials for Inhalation: Physical Changes During the Size Reduction Process" was recently presented at Respiratory Drug Delivery 2008, Arizona, USA.
The interactions of active pharmaceutical ingredients with excipient particles in an inhalation formulation determine the efficiency of the device. For example, unwanted agglomeration of particles or adhesion to device components can have a negative impact on dose uniformity. Such interactions must be carefully optimised to ensure adequate separation of the API and excipient particles upon activation. The surface free energy is an important consideration when formulating a pharmaceutical material since this is a dominant component of adhesion and cohesion phenomena. This can be particularly important when considering APIs used in inhalation formulations since the size reduction process can cause significant changes in surface energy.
The aim of this study was to investigate the surface energy of three polymorphs using carbamazepine as a model compound. Samples were investigated before and immediately after size reduction by micronisation, and after micronisation and storage at ambient laboratory conditions for one month. This work highlights the application of nanoPASS as a comprehensive suite of complementary analytical techniques designed to optimise solid state selection of APIs and proved further insight into the formulation of APIs and excipients.
In the application detailed in the poster, Carbamazepine Forms I, II and III were prepared and confirmed by Powder X-ray Diffraction (PXRD), Raman and Infrared spectroscopy. Surface free energy measurements were based on the adhesive interaction between an atomic force microscope (AFM) probe and single particles of carbamazepine. Humidity was kept to a minimum (~1% RH) and electrostatic charging was minimised prior to each experiment. Measurements were made in a grid pattern across the surfaces of multiple particles. Micronisation was performed using a Sturtevant qualification microniser with a grind pressure of 100 PSI for 10 minutes.
The poster demonstrates the ability to discriminate between three polymorphs or carbamazepine at the single particulate level and with nanoscale lateral resolution. In addition, the researchers identified an increase in the surface energy following micronisation, a change which begins to reverse after storage in ambient conditions. An understanding of such behaviour during this type of processing is crucial in minimising undesirable formulation attributes. Data can be acquired from a few milligrams of material, hence can be applied at an earlier stage of development. This information can aid the rapid screening of pre-formulation materials to understand how the physical properties of an API may change during processing.
For more information on Molecular Profiles' contract research services or to obtain a copy of this poster, please visit www.molprofiles.co.uk or e-mail email@example.com
About Molecular Profiles
Molecular Profiles is a contract service organisation providing analytical research, consultancy and formulation advice to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide. The company is a recipient of a Queen's Award for Enterprise in the Continuous Innovation and Development category. The award saw the company and its complete range of services recognised as one of the UK's most innovative during 2007.
Molecular Profiles' range of services are branded under mpanalytics, mpconsulting and mpformulations.
For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 mail to: